BIO-CANDESARTAN TABLET

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

CANDESARTAN CILEXETIL

Доступно од:

BIOMED PHARMA

АТЦ код:

C09CA06

INN (Међународно име):

CANDESARTAN

Дозирање:

32MG

Фармацеутски облик:

TABLET

Састав:

CANDESARTAN CILEXETIL 32MG

Пут администрације:

ORAL

Јединице у пакету:

100

Тип рецептора:

Prescription

Терапеутска област:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0135220004; AHFS:

Статус ауторизације:

CANCELLED PRE MARKET

Датум одобрења:

2022-07-19

Карактеристике производа

_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35 _
_ _
PRODUCT MONOGRAPH
PR
BIO-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
BIOMED PHARMA
DATE OF PREPARATION:
5950, Côte de Liesse, Suite 100
June 15, 2016
Ville Mont-Royal
Québec H4T 1E2
SUBMISSION CONTROL #: 194909
_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35 _
_ _
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................................
4
ADVERSE REACTIONS
...........................................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................................
16
OVERDOSAGE
.......................................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
19
STORAGE AND STABILITY
.................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................................
22